News

Neuraxpharm appoints Tom Coogan as new Country Manager for Ireland

Europe’s leading central nervous system specialty company…

BioInnovation Institute announces latest cohort of companies entering Venture Lab program

BioInnovation Institute (BII), an international commercial non-profit…

Gadeta announces significant progress in advancing pipeline and TEG platform development

Aim is to develop gamma delta (γδ) T-cell receptor (TCR)-based…

James Brady Joins Verona Pharma as Non-Executive Director

LONDON and RALEIGH, N.C., March 14, 2022 (GLOBE NEWSWIRE) --…

Versameb CEO Klaas Zuideveld to Present at the RNA Leaders World Congress

Presentation demonstrates lead therapeutic candidate VMB-100…

Exact Therapeutics Announces Clinical Trial Update

OSLO/LONDON, 08 March 2022: EXACT THERAPEUTICS AS (“EXACT-Tx”,…

Destiny Pharma Fundraising to raise up to £7.0 million

Destiny Pharma plc (AIM: DEST) (the “Company” or “Destiny…

Neuraxpharm expands its business in Southeast Europe

Acquisition of Brain Therapeutics with operations in Greece, Cyprus…

Novo Holdings Portfolio Company Syndesi Therapeutics acquired by AbbVie

March 1, 2022 Deal value of US$ 1 billion with…

Touchlight and Versameb announce GMP manufacturing supply agreement

Versameb moves forward with its lead asset towards clinical…

Novo Holdings continues to back Biomason by participating in its US$65M Series C Financing

Funds will accelerate wide-scale adoption and commercialisation…

Egetis Therapeutics asks for hugs to increase disease awareness of MCT8 deficiency

February 24, 2022 Stockholm, Sweden, February 24, 2022 –…

We’d love to hear from you

For more information about Optimum Strategic Communications, please get in touch.

© Optimum Strategic Communications.